论文部分内容阅读
目的:对晚期胃癌患者接受卡培他滨和替吉奥进行维持化学治疗的实际临床价值做出评价。方法:选取2017年1月至2018年12月焦作市第二人民医院消化内科一区收治的93例晚期胃癌患者。男55例，女38例，年龄(52.5±7.3)岁，年龄范围为34～78岁。根据维持治疗方案不同分为卡培他滨治疗组、替吉奥治疗组与空白组，每组31例。比较三组患者的治疗效果和预后情况。结果:三组患者治疗效果比较，差异无统计学意义(n P>0.05)。卡培他滨治疗组合患者的疾病进展时间与替吉奥治疗组患者的疾病进展时间比较，差异无统计学意义(n P>0.05)；空白组患者的疾病进展时间[(6.2±1.3)个月]较替吉奥治疗组患者的疾病进展时间[(8.9±1.1)个月]短，差异有统计学意义(n P0.05). The disease progression time of patients in the blank group[(6.2±1.3)months]was shorter than that of patients in the tegafur treatment group[(8.9±1.1)months], with statistically significant difference(n P<0.05). The total survival time of capecitabine treatment group[(14.3±1.6)months] and the tegafur treatment group[(14.8±1.5)months]was significantly different from that of the blank group[(13.2±0.8)months], with statistically significant difference(n P0.05). The incidence of fatigue and anemia among the three groups was statistically significant(n P<0.05).n Conclusion:Both capecitabine and tegafur maintenance chemotherapy can prolong the time of disease progression and are relatively safe in patients with advanced gastric cancer.